agilon health, inc. (AGL) valuation

Bring your own price

Enter a share price and a discount rate — every multiple, the earning-power value and the reverse-DCF below recompute on the spot from agilon health, inc.'s latest SEC EDGAR filings. Change either input and the whole page follows.

Share price (USD)

Discount rate (% per year)

Enter a share price to run the model.

The prefilled 8.9% is a plain CAPM cost of equity at β = 1: the 10-year Treasury yield (4.46%, 2026-06-18, U.S. Treasury 10-yr) plus the U.S. equity risk premium (4.46%, Damodaran 2026-01-01). Build a firmer per-company rate with the cost-of-equity and WACC calculators, then paste it here.

Share price — · awaiting your input

Market Capitalization

Equity value at your price

—

Price-to-Earnings

P/E · Trailing Diluted

—

Earnings Yield

EPS ÷ Price · Trailing

—

Price-to-Free-Cash-Flow

P/FCF · Trailing

—

Free-Cash-Flow Yield

FCF Yield · Trailing

—

Price-to-Sales

P/S · Trailing

—

Price-to-Book

P/B · Latest filing

—

Fundamentals from the filings

Every model input below comes straight from agilon health, inc.'s SEC EDGAR XBRL filings — these are the denominators and bridge inputs the calculator pairs with your price and rate.

Trailing twelve months · TTM as of 2026-03-31 (Q1 FY2026)

Revenue: $5.82B
EBIT (GAAP): -$437.1M
EBIT margin: -7.5%
Operating cash flow: -$50.0M
CapEx: $35.4M
D&A: $28.5M
Free cash flow: -$85.4M
Stock-based comp: $38.7M
YoY revenue growth: -2.8%

CapEx bundles PP&E purchases + capitalised software/intangibles ($22.9M) — the same total the P/FCF and FCF-Yield cards net against operating cash flow.

Balance sheet · 10-Q · period ending 2026-03-31

Cash & equivalents: $140.0M
Total debt: $33.4M
Stockholders' equity: $181.4M
Excess cash: $23.6M

Total debt = Long-term debt (current + noncurrent) ($30.0M) + Operating lease liability ($3.4M) .

Excess cash = total cash − an operating-cash floor of 2% of TTM revenue ($116.4M) that a buyer couldn't pocket without starving operations.

Share count

Diluted shares (TSM-scaled): 16.7M

Method: point-in-time shares outstanding × 1.0038 (latest filer-disclosed diluted ÷ basic ratio). See the diluted-shares methodology for why this count denominates EPV/share and the reverse-DCF equity bridge.

Earning-Power-Value, reverse-DCF, and EV/EBITDA are hidden for this insurer. EPV and the reverse-DCF both anchor on an EBIT margin, but a insurer's "margin" is interest-spread × leverage with non-EBIT investment results mixed in; EV/EBITDA omits deposits and borrowings — the actual funding — so the multiple isn't interpretable. The trailing multiples above (P/E, P/S, P/B, P/FCF) still render, but the right lens here is price-to-tangible-book-value and ROE vs cost of equity — applied manually, outside this page.